2025年依普利酮正版的价格是多少？

Eplerenone can be used to treat adult patients with heart failure and hypertension after myocardial infarction. Its price and correct use have attracted much attention. This article will introduce in detail the latest price information, standard usage and dosage of eplerenone genuine drugs in 2025, as well as medication precautions for special groups, providing patients with a comprehensive medication reference.

What is the price of genuine eplerenone in 2025?

The price of genuine drugs in the international market will remain relatively stable in 2025, and the prices of products from different manufacturers vary.

American Huizhi version

The original drug INSPRA produced by Pfizer has a specification of 50mg*100 tablets, and the price is about US$85 per box.

Indian Lupine version

The generic version of the drug produced by India's Lupine Pharmaceuticals is 50mg*150 tablets, and the reference price is about US$88 per box. Although the unit price is low, the reliability of the source of the drug needs to be confirmed.

After understanding the drug price, mastering the correct usage and dosage is crucial to the therapeutic effect.

Usage and dosage of eplerenone

The usage and dosage of eplerenone need to be adjusted according to the indications and individual patient conditions.

Heart failure treatment

The initial dose is 25 mg once a day, which can be increased to 50 mg once a day after 4 weeks. Serum potassium levels need to be monitored regularly and the dosage adjusted based on test results.

Hypertension treatment

The recommended starting dose is 50 mg once a day, which can be increased to 50 mg twice a day if the effect is not good. The maximum dose does not exceed 100mg/day.

The use of eplerenone in special groups requires special attention to dose adjustment and monitoring.

Eplerenone medication for special populations

Different populations have different metabolism and tolerance of eplerenone, and individualized medication is required.

Elderly patients

The starting dose for patients over 65 years old should be reduced by 25%. Because renal function may decrease, serum potassium and renal function monitoring need to be strengthened.

Patients with renal insufficiency

For patients with a creatinine clearance rate of 30-50mL/min, the dose should be halved. For patients with a creatinine clearance rate below 30mL/min, it is contraindicated. Changes in renal function need to be closely monitored during medication.

Patients with hepatic impairment

The dose should be reduced by 50% in patients with moderate hepatic impairment (Child-Pugh class B). Use with caution in patients with severe liver damage.

Eplerenone is a prescription drug and must be evaluated by a professional physician before use, and relevant examinations must be carried out regularly.